CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
May 20, 2020
 CO28: NEOadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer: The NEO Trial has been closed to accrual after successfully reaching the accrual goal. The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum. Read More |
Transitions in the CCTG Quality of Life Committee LeadershipPublished: May 20, 2020Category: Group updates  After 22 years in his position as QOL committee co-chair, Dr. Michael Brundage is stepping down, to be succeeded by Dr. Winson Cheung. Read More |
May 07, 2020
 The IND216 trial: Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia, has been permanently closed. About the trial: Buparlisib has been shown to shrink tumours in animals. It has been studied in some people and seems promising but it is not clear if it can offer better results than standard treatment. The standard or usual treatment for this disease is chemotherapy, targeted therapy or radiation, either alone or in combination. Read More |
CCTG Genitourinary Disease Site Committee welcomes new chair and modality sub-chairsPublished: May 07, 2020Category: Group updates  The CCTG Genitourinary Disease Site Committee is very honoured to welcome the new chair and modality sub-chairs. Read More |
|
|
April 22, 2020
 CRC9 (NCT04068103), Phase II/III study of Circulating tumor DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA), has been centrally activated. Read More |
COVID-19 Update: CCTG guidance documents and updated FAQPublished: April 22, 2020Category: Group updates  CCTG has developed guidance documents to facilitate continuing patients on trials or how to modify (and document) protocol requirements for individual patient management as needed. Please note that an updated Frequently Asked Questions (FAQs) document has been posted to the CCTG COVID-19 members webpage. Also new are posted links to the previously communicated important memos dated 2020MAR17, 2020MAR27 and 2020APR06. Read More |
